In addition, while most immunotherapies focus upon cytotoxic CD8+ populations, the role of CD4+ Th1 cytotoxic and helper functions is increasingly recognized as necessary to drive anti-tumor immunity [39,40]. The gene discussed is CD8A; the disease is neoplasm.